Fluorinated Neuroactive Steroids for Safer NMDA Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing neuroactive steroids for modulating NMDA receptors have varying degrees of efficacy and stability, leading to potential neurotoxicity and suboptimal therapeutic outcomes for CNS-related conditions.

Innovation Solution

Development of novel neuroactive steroids with specific structural features, such as fluorination on the C17 side chain and secondary or tertiary terminal alcohol, to enhance potency and limit NMDA receptor potentiation, reducing the risk of glutamate-driven neurotoxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If compounds bear a beta-hydrogen at C5, then synthesis is simplified, but NMDA receptor potentiation is reduced

Engineering Contradiction:

Improvesynthesis simplicityVSAvoidNMDA receptor potentiation

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent changes the hydrogen configuration at C5 from beta to alpha position, which maintains synthesis feasibility while significantly improving NMDA receptor potentiation efficacy. This parameter change resolves the contradiction by optimizing the stereochemical configuration to achieve both manufacturability and therapeutic effectiveness.

Inventive Principle:

Principle #35Parameter changes

2Weight of moving object

If compounds lack a methyl at C21, then molecular weight is reduced, but NMDA receptor potentiation is significantly lost

Engineering Contradiction:

Improvemolecular weightVSAvoidNMDA receptor potentiation

Core Design Contradiction:

Weight of moving objectVSReliability

Solution Approach 1:

The patent maintains the methyl group at C21 position as a critical structural feature. This parameter preservation ensures that the compound retains full NMDA receptor potentiation activity while keeping the molecular weight optimized for pharmacokinetic properties. The methyl group is identified as essential for maintaining the desired biological effect.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If compounds achieve high NMDA receptor potentiation, then therapeutic efficacy is improved, but risk of glutamate-driven neurotoxicity increases

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidneurotoxicity risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces specific local structural modifications including disubstitution at C3 with particular groups, fluorination at C17, and specific configurations at C8 and C14. These localized quality changes optimize the compound's interaction with NMDA receptors to achieve potentiation while reducing off-target effects and neurotoxicity risk through precise structural control.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent optimizes multiple structural parameters simultaneously including substitution patterns at C3, fluorine positioning at C17, and stereochemical configurations. These parameter optimizations work together to achieve the desired therapeutic window by enhancing efficacy while minimizing neurotoxicity through controlled receptor potentiation.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12617814B2Neuroactive steroids and methods of use thereof

Publication Date: 2026.05.05 SAGE THERAPEUTICS LLC

AI summary

3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.